Smallpox alphavaccine

Smallpox alphavaccine refers to a vaccine platform that utilizes alphavirus replicon technology, primarily derived from the Venezuelan Equine Encephalitis Virus (VEEV), to express antigens from the Variola virus or Vaccinia virus (Hooper et al., 2000, Virology). This platform is designed to induce protective immunity against smallpox by delivering genetic sequences for critical viral proteins such as L1, B5, A27, and A33, which are essential for viral entry and dissemination (Ying et al., 2010, Vaccine). The alphavirus vector acts as a potent adjuvant, stimulating robust humoral and cellular immune responses, including the production of neutralizing antibodies and the activation of T-cells (Pushko et al., 1997, Virology). Smallpox, caused by the Variola virus, is a severe infectious disease characterized by high fever and a progressive skin rash, which was eradicated globally but remains a biosecurity concern (CDC, 2021). The alphavaccine platform aims to provide a safer alternative to traditional live-virus vaccines by using replication-deficient particles that cannot produce new infectious virions in the host. While it is a therapeutic candidate, it is not a biological target molecule such as a receptor or enzyme, but rather a delivery system for immunization.

Other names

Alphavirus-based smallpox vaccineVEEV-based smallpox vaccineAlphavirus replicon vaccine for smallpoxVEEV replicon particles (VRP) smallpox vaccine

Induction of protective immunity through the expression of Variola or Vaccinia virus antigens (e.g., L1, B5, A27, A33) using an alphavirus replicon system (Hooper et al., 2000).